September 12, 2025

Autologous Cytokine-induced Killer Cell Combination Therapy Enhances Response to Immune Checkpoint Inhibitors in Patients with Refractory Clear Cell Renal Cell Carcinoma

View Full Paper

Ask AI

Bookmark

Authors

SLShuzhan LiHainan University JQJing QinHong Kong Polytechnic University QSQian SunSuzhou University of Science and Technology

Discussion

Member takes

Implication

Clinical study shows improved overall survival and response rates in refractory ccRCC patients using combination therapy with anti-PD-1 and CIK cells, suggesting effective treatment strategies.

Key Points

CIK cell therapy improves the objective response rate to immune checkpoint inhibitors in patients with refractory ccRCC.
In the trial group, the objective response rate was 55.6%, significantly higher than the 41.7% observed in the control group.
Patients receiving combination therapy showed improved median progression-free survival of 28.5 months compared to 8.67 months for the control.
No new safety signals were identified, indicating that CIK cell therapy can be safely integrated with anti-PD-1 treatment.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68d41c09713b0b5dfea657ec https://doi.org/10.21203/rs.3.rs-7440160/v1

View Full Paper

Ask AI

Bookmark

Implication

Clinical study shows improved overall survival and response rates in refractory ccRCC patients using combination therapy with anti-PD-1 and CIK cells, suggesting effective treatment strategies.

Autologous Cytokine-induced Killer Cell Combination Therapy Enhances Response to Immune Checkpoint Inhibitors in Patients with Refractory Clear Cell Renal Cell Carcinoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Autologous Cytokine-induced Killer Cell Combination Therapy Enhances Response to Immune Checkpoint Inhibitors in Patients with Refractory Clear Cell Renal Cell Carcinoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider